<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955421</url>
  </required_header>
  <id_info>
    <org_study_id>E100VG250</org_study_id>
    <secondary_id>Tarceva100vsIressa250</secondary_id>
    <nct_id>NCT01955421</nct_id>
  </id_info>
  <brief_title>Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc</brief_title>
  <acronym>NSCLC EGFR TKI</acronym>
  <official_title>A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose&#xD;
      erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced&#xD;
      non-small cell lung cancer who harbor EGFR mutations. The primary endpoint is disease control&#xD;
      rate (DCR) and the key secondary endpoint is progression free survival (PFS). A total of 224&#xD;
      eligible patients will be randomized to receive either erlotinib 100mg daily or gefitinib&#xD;
      250mg daily in a 1:1 ratio until patients experience disease progression. Independent&#xD;
      assessment of the major endpoints will be completed in a treatment-blinded manner.&#xD;
      Randomization will be stratified based on treatment-lines (first-line vs. maintenance vs.&#xD;
      second-line therapy). Tumor response and progression will be assessed according to RECIST&#xD;
      1.1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>rash, diarrhea, ILD, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Advanced Stage Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to buy and receive erlotinib 100mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to buy and receive gefitinib 250mg qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib 100mg qd</intervention_name>
    <arm_group_label>Erlotinib100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib 250mg qd</intervention_name>
    <arm_group_label>Gefitinib250</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of advanced stage NSCLC (stage IIIB or IV) which is confirmed by histology&#xD;
             or cytology methods.&#xD;
&#xD;
          2. Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion&#xD;
             or an exon 21 L858R point mutation.&#xD;
&#xD;
          3. Measurable disease according to RECIST1.1.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) score of 0-2&#xD;
&#xD;
          5. Adequate organ function, defined as all of the following:&#xD;
&#xD;
               1. LVEF &gt;50% or within institution normal values.&#xD;
&#xD;
               2. Absolute neutrophil count (ANC)&gt;1500/mm3.&#xD;
&#xD;
               3. Platelet count &gt;75,000/mm3&#xD;
&#xD;
               4. Estimated creatinine clearance&gt;45m1/min.&#xD;
&#xD;
               5. Total bilirubin&lt;1.5 times institutional ULN (Patients with Gilbert's Syndrome&#xD;
                  total bilirubin must be &lt;4 times institutional ULN).&#xD;
&#xD;
               6. Aspartate amino transferase (AST) or alanine amino transferase (ALT) &lt; three&#xD;
                  times the institutional upper limit of normal (ULN) (if related to liver&#xD;
                  metastases&lt;five times institutional ULN).&#xD;
&#xD;
          6. Recovered from any previous therapy related toxicity to ≤CTCAE Grade 1 at study entry&#xD;
             (except for stable sensory neurupethy ≤CTCAE Grade 2 and alopecia).&#xD;
&#xD;
          7. Ability to take oral medication in the opinion of the investigator.&#xD;
&#xD;
          8. Age ≥ 18 years.&#xD;
&#xD;
          9. Written informed consent that is consistent with ICH-GCP guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with EGFR directed small molecules or antibodies.&#xD;
&#xD;
          2. Radiotherapy within 4 weeks prior to randomization, except as follows:&#xD;
&#xD;
               1. Palliative radiation to target organs other than chest may be allowed up to 2&#xD;
                  weeks prior to randomization&#xD;
&#xD;
               2. Single dose palliative treatment for symptomatic metastasis outside above&#xD;
                  allowance to be discussed with sponsor prior to enrolling.&#xD;
&#xD;
          3. Active brain metastases (stable for &lt;4 weeks, symptomatic, or leptomeningeal disease).&#xD;
             Dexamethasone therapy will be allowed if administered as a stable dose for at least 4&#xD;
             weeks before randomization.&#xD;
&#xD;
          4. Any other current malignancy or malignancy diagnosed within the past three (3) years&#xD;
             (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ&#xD;
             prostate cancer).&#xD;
&#xD;
          5. Known pre-existing interstitial lung disease.&#xD;
&#xD;
          6. Significant or recent acute gastrointestinal disorders with diarrhea as a major&#xD;
             symptom e.g. Crohn's disease, malabsorption or CTC grade &gt;2 diarrhoea of any&#xD;
             aetiology, based on investigator assessment.&#xD;
&#xD;
          7. History or presence of clinically relevant cardiovascular abnormalities such as&#xD;
             uncontrolled hypertension, congestive heart failure NYHA classification of 3 (Refer to&#xD;
             Appendix 10.4), unstable angina or poorly controlled arrhythmia as determined by the&#xD;
             investigator. Myocardial infarction within 6 months prior to randomisation.&#xD;
&#xD;
          8. Any other concomitant serious illness or organ system dysfunction which in the opinion&#xD;
             of the investigator would either compromise patient safety or interfere with the&#xD;
             evaluation of the safety of the test drug.&#xD;
&#xD;
          9. Women of child-bearing potential and men who are able to father a child, unwilling to&#xD;
             be abstinent or use adequate contraception prior to study entry, for the duration of&#xD;
             study participation and for at least 2 months after treatment has ended. Adequate&#xD;
             methods of contraception and women of Child-Beanng Potenial are discussed in Section&#xD;
             4.2.2.3.&#xD;
&#xD;
         10. Female patients of childbearing potential (see Section 4.2.2.3) who are nursing or are&#xD;
             pregnant.&#xD;
&#xD;
         11. Patients unable to complv with the protocol in the opinion of the investigator.&#xD;
&#xD;
         12. Active hepatitis B infection (detined as presence of Hepatitis B DNA), active&#xD;
             hepatitis C infection (defined as vresence of Hepatitis C RNA) and/or known HIV&#xD;
             carrier.&#xD;
&#xD;
         13. Known or suspected active drug or alcohol abuse in the opinion of the investigator.&#xD;
&#xD;
         14. Requirement for treatment with any of the prohibited concomitant medications listed in&#xD;
             Section 4.2.3.&#xD;
&#xD;
         15. Any contraindications for therapy with gefitinib or erlotinib.&#xD;
&#xD;
         16. Known hypersensitivity to erlotinib, gefitinib or the exipients of any of the trial&#xD;
             drugs&#xD;
&#xD;
         17. Major surgery within 4 weeks of starting study treatment.&#xD;
&#xD;
         18. Use of any investigational drug within 4 weeks of randomisation (unless a longer time&#xD;
             period is required by local regulations or by the guidelines for the investigational&#xD;
             product).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Cancer Center of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhua Liang, MD</last_name>
      <phone>8613710249454</phone>
      <email>liangwh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenhua Liang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>stage IIIB</keyword>
  <keyword>stage IV)</keyword>
  <keyword>confirmed by histology or cytology methods</keyword>
  <keyword>Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

